European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

United Kingdom - English - myHealthbox

novartis vaccines and diagnostics - neisseria meningitidis group c (strain c11) oligosaccharide, corynebacterium diphtheriae crm197 protein , adsorbed on aluminium - suspension for injection - 10micrograms, 12.5 to 25.0micrograms, 0.3 to 0.4mg al 3+ - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

United Kingdom - English - myHealthbox

novartis vaccines and diagnostics - neisseria meningitidis group c (strain c11) oligosaccharide, corynebacterium diphtheriae crm197 protein , adsorbed on aluminium - suspension for injection - 10micrograms, 12.5 to 25.0micrograms, 0.3 to 0.4mg al 3+ - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1v) 2009 virus.focetria should be used in accordance with official guidance.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis vaccines and diagnostics s.r.l. - a/california/7/2009 (h1n1)pdm09-derived strain used (nymc x-181) a/texas/50/2012 (h3n2) derived strain used (nymc x-233a) b/massachusetts/2/2012-like strain used b/massachusetts/2/2012 wild type - suspension for injection

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis vaccines and diagnostics s.r.l. - a/california/7/2009 (h1n1)pdm09-derived strain used (nymc x-181) a/texas/50/2012 (h3n2) derived strain used (nymc x-233a) b/massachusetts/2/2012-like strain used b/massachusetts/2/2012 wild type - suspension for injection - 0.5

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - influenza virus surface antigens (haemagglutinin and neuraminidase) a/vietnam/1194/2004 (h5n1) - like strain used (nibrg-14) - injection, suspension - >or= 7.5 ug ha

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis vaccines & diagnostics pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -